AIM

The aim of this study was to identify price differences between ASMR IV drugs and their comparators.

METHODS

Using the French HAS database we started by collecting all the drugs which obtained an ASMR IV between January 2016 and December 2018. Only the drugs in first-registration (“primo-inscription”) were included. 25 drugs were selected. Then, we split those in two groups: orphan drugs and other drugs. For each group, two sub groups were created: oncology drugs VS others. Finally, we identified both the prices of these ASMR IV and the prices of their comparators considered as the reference; and we calculated the difference between them.

RESULTS

We observed that the price level of oncology drugs is equal to the price level of their referents (ASMR IV). Moreover, oncology drugs can have a premium price when the comparator is a chemotherapy. In some cases, a premium price can be obtained however, only one case has been observed.

In contrast, for the other drugs (no anticancer drugs), the price of ASMR IV can be higher than its comparators only if:

There is a demonstration of superiority in morbi-mortality (sacubitril, valsartan, ENTRESTO); or if there is a “breakthrough therapy” such as the arrival of cell therapy (darvadstrocel)) or MaB in Asthma.

.CONCLUSION

An ASMR of IV may possibility lead to a premium price as would get an ASMR III. However, these prices should be under a manager entry agreement and the difference between the list price and net price is probably significant (35 to 50 %).

To conclude with, two effects need to be assessed: the dynamic in the short terms of the net price between 24 to 36 months and the effect of the arrival of news comparators.